Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Published on :

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development [….]

Rockville’s Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Published on :

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]

Weekly Roundup of COVID-19 Progress From T-Cell to Microbiome Therapies and FDA Emergency Use Applications

Published on :

Weekly Roundup of COVID-19 Progress From T-Cell to Microbiome Therapies and FDA Emergency Use Applications April 21, 2020 Organizations from across the BioHealth Capital Region (BCHR) continue to pivot research, [….]

Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies

Published on :

Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies Leidos’s ExGloH Leverages Entrepreneurial Science and Industry-Leading Support Infrastructure to Improve Global Health June [….]

4 Vaccine and Immunotherapy Companies in Maryland That Are Redefining the Capabilities of Modern Medicine

Published on :

4 Vaccine and Immunotherapy Companies in Maryland That Are Redefining the Capabilities of Modern Medicine Maryland’s World Leading Vaccine Hub Showcased at Fourth Annual MTC Life Science Breakfast January 22, [….]

Q&A with Immunomic’s Teri Heiland, PhD: What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy

Published on :

Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018   Teri Heiland, Ph.D. is the Senior Vice President [….]